Amid heated controversy over drug prices, Sanofi (SNY) is the latest large pharmaceutical company to release top-line numbers indicating average prices for its medicines fell last year, after accounting for rebates and discounts.

Specifically, the company posted a brief summary stating the average wholesale — or list— price for its drugs increased 1.6 percent in 2017, but pricing actually declined by 8.5 percent when subtracting rebates and discounts paid to pharmacy benefit managers, or PBMs, and health plans. In 2016, the average price hike was 4 percent, but the net price fell 2.1 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Per Bloomberg, net revenue for Sanofi last year was 8 Billion Euros, with a profit margin of 23.3% – they did well with such a net price decrease, don’t you think?

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy